Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?

FTAI Aviation Ltd. (NASDAQ:FTAI) shares plummeted 35.42% after short seller firm Muddy Waters Research announced they initiated a short position in the company.
Moderna, Inc. (NASDAQ:MRNA) stock plunged 19.38% after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below analyst estimates of $2.951 billion. Morgan Stanley maintained an Equal-Weight rating and lowered the price forecast from $70 to $38.
GameStop Corporation (NYSE:GME) stock declined 14.86%. In a recent X post, CNBC's Jim Cramer steered investors toward quantum stocks, suggesting they reinvest gains from GameStop into Rigetti Computing Inc (NASDAQ:RGTI).
Snap Inc. (NYSE:SNAP) shares dipped 12.91% following a report suggesting that Trump is considering an executive order to save TikTok from a U.S. ban.
Rocket Lab USA, Inc. (NASDAQ:RKLB) shares were down 10.81%. The company disclosed that its second Pioneer spacecraft for Varda Space Industries, Inc. is successfully operating in orbit.
Natera, Inc. (NASDAQ:NTRA) stock lost 9.51% last week despite Guggenheim raising the price forecast from $170 to $200. The company is due to provide a roadmap and outlook at the J.P. Morgan Healthcare Conference.
Eli Lilly and Company (NYSE:LLY) stock decreased 9.27% after the company issued FY24 revenue guidance below the previous estimate.
ICON plc (NASDAQ:ICLR) stock fell 9.22% after the company issued FY25 guidance with its midpoint below estimates.
BioNTech SE (NASDAQ:BNTX) shares declined 8.89% after Moderna issued 2025 revenue guidance below analyst estimates.
Novo Nordisk A/S (NYSE:NVO) shares fell 8.89% after Ozempic and Wegovy were included in a list of 15 medications for Medicare drug price negotiations.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares tumbled 8.68%. The company initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the Unified Patent Court (UPC) in Munich, Germany.